Benefits
Cardiovascular Support
Both components have independent CV evidence: magnesium for BP reduction (modest, ~3-5 mmHg in meta-analyses) and arrhythmia prevention; taurine for BP, vascular function, and modest cardiac contractility effects. The combination's positioning is mechanistically rational; head-to-head human RCTs vs other Mg forms are limited.
Blood Pressure Modest Reduction
Magnesium meta-analyses show modest BP reduction (Zhang 2016 et al.); taurine RCTs (Sun 2016 in prehypertensives) show ~7 mmHg systolic reduction. Combined effects plausible but not definitively studied.
Animal Evidence for Hypertension
Animal studies (Sprague-Dawley hypertensive rats) show magnesium taurate significantly reduces blood pressure. Human translation requires confirmation in proper RCTs.
Sleep and Anxiety
Taurine independently has GABAergic and inhibitory effects; combined with magnesium may support sleep and anxiety reduction. Modest evidence.
Migraine Prevention
Magnesium content provides migraine prevention benefit (AHS/AAN Level B). Taurine adjunctive.
Mechanism of action
Magnesium Vascular Effects
Magnesium relaxes vascular smooth muscle by competing with calcium at L-type calcium channels and increasing nitric oxide bioavailability — contributing to BP reduction.
Taurine Vascular Effects
Taurine improves endothelial function, reduces oxidative stress, modulates calcium handling in cardiac tissue, and has direct antihypertensive effects via central nervous system mechanisms.
Cardiac Arrhythmia Prevention
Magnesium is critical for cardiac electrophysiology; deficiency predisposes to arrhythmias. IV magnesium is established treatment for torsades de pointes; oral magnesium for chronic AF prevention has modest evidence.
Acetyl-Taurate Variant
Magnesium acetyl-taurate is a newer variant proposed to cross blood-brain barrier more readily; rat studies (Uysal 2018) showed it had second-highest tissue penetration after malate. Human evidence limited.
Clinical trials
Double-blind, placebo-controlled clinical trial in 120 prehypertensive adults receiving taurine vs placebo. (Sun et al. 2016, Hypertension)
120 prehypertensive adults.
Taurine significantly reduced clinic systolic BP (~7.2 mmHg) and 24-hour ambulatory SBP. Improved endothelial function. Used as evidence supporting magnesium taurate combination — though trial used taurine alone, not the magnesium chelate.
Multiple animal studies in spontaneously hypertensive rats showing magnesium taurate reduces BP and improves vascular function.
Animal models.
Consistent BP-lowering effects in animal models. Critical caveat: animal-to-human translation requires direct human clinical trials of the chelate vs other magnesium forms — these are limited.